Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02561351

Enrollment

Registered

2015-09-28

Start date

2013-09-30

Completion date

2015-09-30

Last updated

2016-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Keywords

bronchial asthma, fractional exhaled nitric oxide (FeNO), asthma exacerbation

Brief summary

The purpose of this study is to determine mean or median of fractional exhaled nitric oxide (FeNO) in Thai atopic asthmatic children that divided into subgroups due to asthma exacerbation according to the global initiative for asthma guideline.

Detailed description

From many previous studies, fractional exhaled nitric oxide (FeNO) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients. In Thailand, this field of study is less extend, especially in children population. The investigators hypothesized that patients with asthma exacerbation may have high level of fractional exhaled nitric oxide (FeNO) than non exacerbation group. It is therefore desirable to examine the association between fractional exhaled nitric oxide (FeNO) and asthma exacerbation among atopic asthmatic Thai children and will be the main objective of this research.

Interventions

OTHERFeNO measurement

FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

7 Years to 20 Years

Healthy volunteers

Inclusion criteria

* clinical diagnosis of atopic bronchial asthma follow up in clinic of allergy and clinical immunology, Siriraj hospital

Exclusion criteria

* smoker or past history of smoking * chronic disease eg. HIV infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, COPD, bronchiectasis * drink ethanol within 48 hours before enrollment * history of upper or lower respiratory tract infection within 6 weeks before enrollment drink caffeine within day before enrollment during pregnancy history of systemic steroid use within 8 weeks before enrollment

Design outcomes

Primary

Measure	Time frame	Description
Occurrence of asthma exacerbation in the studied cases with different FeNO levels	1 year	Occurrence of asthma exacerbation in 1 year after the study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026